Basma Abdulhadi is an Endocrinology/Metabolic physician affiliated with University of Alabama at Birmingham. OpenAlex indexes 22 publications with 301 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?
Sponsor: Albert Einstein Healthcare Network
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
79%GLP-1 receptor agonist37.3%Ozempic48%Mounjaro38%Trulicity14%Part D<11 patientsInsulin Analog20%Lantus Solostar38%Tresiba Flextouch U-10020%Novolog Flexpen15%Basaglar Kwikpen U-10015%Novolog13%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
16.1%l-Thyroxine16.1%Levothyroxine Sodium100%Part D≥18 patientsSensory organs
4.9%Corticosteroid4.9%Hydrocortisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 12392 Decoding LADA: A Closer Look At A Suspected Case Influenced By Prior IVIG Therapy
Journal of the Endocrine Society
2024 - THE UNSEEN CONSEQUENCES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) IN PATIENTS UNDERGOING UPPER ENDOSCOPY
Gastrointestinal Endoscopy
2024 - THE UNSEEN CONSEQUENCES OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA) IN PATIENTS UNDERGOING UPPER ENDOSCOPY
Gastrointestinal Endoscopy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Vera Bittner
University of Alabama at Birmingham
David Standaert, MD, PhD
University of Alabama at Birmingham
Erik Roberson
University of Alabama at Birmingham
Bruce Korf
University of Alabama at Birmingham
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”